Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates:

Shockwave Medical Provides Quarterly Earnings Release Dates for 2024

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now

SANTA CLARA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, which is being held from Monday, January 8 to Thursday, January 11, 2024, in San Francisco, CA.

Shockwave Medical to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Shockwave Medical is a med-tech company that utilizes Intravascular Lithotripsy technology to treat cardiovascular diseases. The company has a significant market presence and stands to capture a significant share of the expanding global cardiovascular intervention market. Shockwave has impressive financial metrics, positioning it as a standout choice for investors seeking profitability and exponential growth.

Shockwave Medical: Timing The Waves Of Opportunity

Shockwave Medical is a pioneer in intravascular lithotripsy and has recently experienced a reset valuation due to temporary factors. The company has shown strong revenue growth in 2023, but is facing challenges in its current peripheral business and uncertainty in 2024. Despite these obstacles, Shockwave Medical is navigating through the hiccups and working towards continued success.

Shockwave Medical: Optimal 2024 Setup For Gains

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

AtriCure

DexCom

Medtronic

The article discusses the factors that have led to the undervaluation of the MedTech sector, including the rise in interest rates, opposition to corporate acquisitions by the FTC, and the impact of GLP-1-based treatments. I defend the importance of MedTech interventions and highlight several companies in the sector that are poised for recovery, including DexCom, Medtronic, Shockwave Medical, and AtriCure. The article provides charts and analysis for each of the mentioned companies, suggesting potential buying opportunities for investors.

Buying These 4 Hated Names Devastated By The GLP-1 Hype

SANTA CLARA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th Annual Healthcare Conference, which is being held from Tuesday, November 28 to Thursday, November 30, 2023 in New York, NY.

Shockwave Medical to Participate in the Piper Sandler 35th Annual Healthcare Conference

CRISPR Therapeutics

Incyte

When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical trials, as companies with early stage drugs are too risky for me.

3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024

One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across Sexes One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across Sexes

New Shockwave Coronary IVL Publication Shows Similar Outcomes in Women And Men

Shockwave Medical, Inc. aims to transform the treatment of calcified cardiovascular disease with intravascular lithotripsy. The company has experienced rapid sales growth and profitability in recent years. Despite slower sales growth, I remain optimistic about Shockwave Medical and plan to buy more shares at these levels.

Shockwave Medical: Buying The Dip

Melco Resorts and Entertainment

Stock markets were broadly higher on Tuesday. However, Shockwave Medical shares fell despite strong results from the medical device maker in the third quarter of 2023.

A Bull Market Might Be Coming, but These 2 Stocks Aren't Along for the Ride Just Yet

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical, Inc. (NASDAQ:SWAV ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Debbie Kaster - Vice President, Investor Relations Doug Godshall - President and Chief Executive Officer Isaac Zacharias - President and Chief Commercial Officer Dan Puckett - Chief Financial Officer Robert Fletcher - Senior Vice President, Marketing & Market Access Conference Call Participants Patrick Wood - Morgan Stanley Travis Steed - Bank of America Adam Maeder - Piper Sandler Larry Biegelsen - Wells Fargo Mike Matson - Needham & Company Imron Zafar - Deutsche Bank Michael Polark - Wolfe Research Mike Kratky - Leerink Danielle Antalffy - UBS Operator Good afternoon and welcome to Shockwave's Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Shockwave Medical, Inc. (SWAV) Q3 2023 Earnings Call Transcript

Shockwave Medical (SWAV) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.92 per share a year ago.

Shockwave Medical (SWAV) Q3 Earnings and Revenues Beat Estimates

SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended September 30, 2023.

Shockwave Medical Reports Third Quarter 2023 Financial Results

ShockWave Medical (SWAV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy ShockWave Medical (SWAV) Ahead of Earnings?

SANTA CLARA, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that as part of the Calendar Year 2024 Physician Fee Schedule (PFS) final rule, the U.S. Centers for Medicare & Medicaid Services (CMS) has established a Category I Current Procedural Terminology (CPT®) add-on code for procedures involving coronary Intravascular Lithotripsy (IVL).

Centers for Medicare & Medicaid Services Establishes New Category I CPT® Add-On Code for Coronary IVL

After reaching an important support level, Shockwave Medical (SWAV) could be a good stock pick from a technical perspective. SWAV surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

Shockwave Medical (SWAV) Crossed Above the 50-Day Moving Average: What That Means for Investors

After reaching an important support level, Shockwave Medical (SWAV) could be a good stock pick from a technical perspective. SWAV surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Shockwave Medical (SWAV) Just Overtook the 20-Day Moving Average

Shockwave Medical (SWAV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shockwave Medical (SWAV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

SANTA CLARA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the third quarter 2023 after market close on Monday, November 6, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2023 Results and Participation in Upcoming Investor Conference

The mean of analysts' price targets for Shockwave Medical (SWAV) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 27.54% Upside in Shockwave Medical (SWAV): Can the Stock Really Move This High?

Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.

Shockwave Medical (SWAV) Announces IVL Studies' Positive Results

Shockwave C2+ Debut Joins Packed Shockwave Agenda at Transcatheter Cardiovascular Therapeutics Conference in San Francisco

News for Shockwave Medical Stock (SWAV)